Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02546102Phase 3Suspended

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Role: lead

NCT02049489Phase 1Completed

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

Role: lead

NCT01280552Phase 2Completed

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Role: lead

All 3 trials loaded